Chronic Obstructive Pulmonary Disease: Economic Burden in Russia and European Countries (Review)
- 31 March 2026
- journal article
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 14 (1)
Abstract
INTRODUCTION. Chronic obstructive pulmonary disease (COPD) is a leading cause of death and significant economic losses for the healthcare system. While there is a trend towards decreasing COPD incidence in Europe, Russia saw the incidence increase by 5%, and the economic burden rose from 0.20% to 0.34% of GDP in 2022–2023. International and nationwide best practices necessitate a further analysis to identify the ways of reducing financial burden on the Russian healthcare system. AIM. This study aimed to identify and evaluate feasibility for the most effective ways to reduce the financial burden when managing COPD patients in the Russian Federation. DISCUSSION. Key differences in COPD epidemiology and cost structure were identified between Russia and EU countries. In the European Union (2001–2019), COPD incidence decreased among men (–9.7%) and increased among women (+4.3%) due to higher smoking rates. In Russia, the incidence continued to grow (+5%), while the mortality remained high (26% of the total death causes). In the EU, main direct costs were attributed to inpatient care (35–64%) and drug therapy (~25%), while the share of indirect costs reached 61–83%. Russian cost structure differed: the share of indirect costs was 92.6%, while among the direct costs, 76.1% was attributed to medicines supply, and only 18.7% covered inpatient care. Effective burden reduction included: smoking cessation (reduced exacerbation risk by 39.7%; hazard ratio 0.65 for abstinence >10 years); prophylactic vaccinations (reduced hospitalizations by 50%, while vaccine refusal increased mortality 162-fold); modern pharmacotherapy (triple therapy: long-acting anticholinergic agents + long-acting beta2-agonists + inhaled glucocorticoids, reduced exacerbation frequency by 24% and mortality by 49%), and pulmonary rehabilitation (OR for hospital readmissions 0.44) still presented poorly in Russia (~10%). CONCLUSIONS. To reduce COPD economic burden in the Russian Federation, it is necessary to increase the coverage with preventive measures (tobacco control programs, immunization), develop pulmonary rehabilitation programs using digital technologies, implement modern pharmacotherapy regimens, and improve physicians’ expertise via continuing medical education.Keywords
This publication has 60 references indexed in Scilit:
- Association between pneumonia hospitalisation and long-term risk of cardiovascular disease in Chinese adults: a prospective cohort studyeClinicalMedicine, 2022
- The economic burden of chronic obstructive pulmonary disease (COPD) in Europe: results from a systematic review of the literatureThe European Journal of Health Economics, 2019
- Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary diseaseCochrane Database of Systematic Reviews, 2019
- Influenza vaccine for chronic obstructive pulmonary disease (COPD)Cochrane Database of Systematic Reviews, 2018
- Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary diseaseCochrane Database of Systematic Reviews, 2016
- Prevalence of Influenza Vaccination in Chronic Obstructive Pulmonary Disease Patients and Impact on the Risk of Severe ExacerbationsArchivos de Bronconeumología, 2016
- Long-acting beta2 -agonist in addition to tiotropium versus either tiotropium or long-acting beta2 -agonist alone for chronic obstructive pulmonary diseaseCochrane Database of Systematic Reviews, 2015
- Tiotropium versus placebo for chronic obstructive pulmonary diseaseCochrane Database of Systematic Reviews, 2014
- Long-acting beta2-agonists for chronic obstructive pulmonary diseaseCochrane Database of Systematic Reviews, 2013
- The Effects of Smoking Cessation on the Risk of Chronic Obstructive Pulmonary Disease ExacerbationsJournal of General Internal Medicine, 2009